BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
A shareholder associated with BIOA has filed a notice under Rule 144 to sell 7,433 shares of common stock through Fidelity Brokerage Services LLC on 02/02/2026 on the NASDAQ. The filing lists an aggregate market value of $139,368.75 for this planned sale and notes 35,855,037 shares of the same class outstanding.
The shares to be sold were acquired by exercising stock options granted on 07/01/2020 and 05/29/2022, with 5,433 and 2,000 shares, respectively, paid for in cash on 02/02/2026. The shareholder also sold common shares in the last three months, including 68,897 shares on 12/04/2025, 18,000 shares on 12/09/2025, and 7,433 shares on 01/02/2026, for stated gross proceeds in each case.
BioAge Labs, Inc. entered into an underwriting agreement to sell 5,897,435 shares of common stock at $19.50 per share in a public offering, with underwriters holding a 30-day option to buy up to an additional 884,615 shares. The transaction is being conducted under the company’s effective shelf registration statement on Form S-3. BioAge estimates net proceeds of about $107.6 million after underwriting discounts and expenses, assuming the option is not exercised.
The company plans to use these funds, together with existing cash, cash equivalents and marketable securities, to support research, clinical and process development and manufacturing for its product candidates, including BGE-102 and its NLRP3 and APJ programs, as well as for working capital, capital expenditures, reduction of indebtedness and other general corporate purposes. Closing of the offering is expected on January 23, 2026, subject to customary conditions.
BioAge Labs, Inc. is conducting a primary offering of 5,897,435 shares of common stock at $19.50 per share, with gross proceeds of about $115.0 million and estimated net proceeds of about $107.6 million. Underwriters have a 30‑day option to buy up to 884,615 additional shares, which would raise net proceeds to roughly $123.9 million if fully exercised.
The company is a clinical‑stage biopharmaceutical developer focused on metabolic diseases, led by its NLRP3 inhibitor BGE‑102 and APJ agonist programs for obesity. As of September 30, 2025, it had 35,850,037 shares outstanding, which would rise to 41,747,472 shares after this offering (excluding the option). BioAge estimates it held about $285.1 million in cash, cash equivalents and marketable securities as of December 31, 2025.
Net proceeds, together with existing cash, are intended to fund research, clinical and process development and manufacturing for BGE‑102 and its NLRP3 and APJ programs, as well as working capital, capital expenditures, debt repayment and other general corporate purposes. Based on current plans, BioAge believes this funding, combined with its existing balance, will support operations and capital needs through 2029, though it may still seek additional capital in the future.
BioAge Labs, Inc. CFO Dov A. Goldstein reported an option exercise and related stock acquisition. On January 16, 2026, he exercised a stock option for 3,542 shares of common stock at an exercise price of $4.38 per share, coded as an "M" transaction.
The derivative table shows this option carried a conversion price of $4.38 and an expiration date of February 17, 2035. Following the transaction, Goldstein held 25,950 shares of BioAge common stock directly and 166,458 stock options directly. The option vests in equal monthly installments of 1/48th of the total award, starting on February 1, 2025, contingent on continued service.
BioAge Labs, Inc. is offering $75,000,000 of its common stock in a primary public offering under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $11,250,000 of shares. The company’s stock trades on the Nasdaq Global Select Market under the symbol “BIOA.” BioAge is a clinical-stage biopharmaceutical company focused on metabolic diseases such as obesity, led by BGE-102, an orally available, brain-penetrant NLRP3 inhibitor now in a Phase 1 SAD/MAD trial, and APJ agonist programs targeting obesity with oral and injectable candidates. As of December 31, 2025, BioAge preliminarily estimates $285.1 million in cash, cash equivalents and marketable securities, and currently expects existing cash plus offering proceeds to fund operations and capital needs through 2029. Net proceeds are intended mainly for research, clinical and manufacturing activities for BGE-102 and the NLRP3 and APJ programs, as well as working capital and general corporate purposes.
BioAge Labs, Inc. filed a current report describing an indication expansion for its oral NLRP3 inhibitor BGE-102 and outlining upcoming clinical milestones. The company plans to start a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) in mid-2026.
In a preclinical DME model, oral BGE-102 showed dose-dependent preservation of retinal vascular integrity, with near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity. BGE-102 has shown favorable tolerability to date in an ongoing Phase 1 trial, alongside robust reductions in inflammatory biomarkers such as hsCRP, IL-6, and IL-1β.
The development plan includes completing the Phase 1 trial with full data in the first half of 2026, starting a Phase 2a proof-of-concept trial in obesity with cardiovascular risk factors in the first half of 2026, initiating the DME Phase 1b/2a trial in mid-2026, and targeting data readouts for the cardiovascular trial in the second half of 2026 and for the DME trial in mid-2027.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein reported a same-day option exercise and share sales. On January 13, 2026, he exercised stock options for 27,000 shares of common stock at an exercise price of $8.39 per share, then sold 27,000 shares in multiple transactions at weighted-average prices of $18.4278, $19.4526, $20.5392 and $21.0808 per share. A footnote states that at least one transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2024. After these trades, he holds 22,408 shares of common stock directly, and the option award provides for monthly vesting and an early exercise feature.
BioAge Labs, Inc. Chief Executive Officer and director Kristen Fortney reported selling 233,107 shares of the company’s common stock on January 13, 2026. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2024, which is designed to allow insiders to systematically trade shares over time.
The shares were sold at a weighted average price of $18.1163 per share, with individual sale prices ranging from $18.00 to $18.385 per share. After this transaction, Fortney beneficially owns 976,949 shares of BioAge Labs common stock in direct ownership.
A holder of BioAge Labs, Inc. common stock has filed a notice under Rule 144 to sell 233,107 shares of common stock through Raymond James & Associates on the NASDAQ, with an approximate sale date of 01/13/2026. The filing lists an aggregate market value of these planned sales of $4,195,926.00 and states that 35,855,037 shares of the issuer’s common stock are outstanding.
The shares to be sold relate to a prior restricted stock purchase dated 08/14/2015, when 1,210,056 common shares were acquired from BioAge Labs, Inc. and paid for by check. By signing the notice, the person for whose account the securities are to be sold represents that they do not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
BIOA filed a Form 144 notice for a planned sale of 27,000 shares of its common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $531,828.03. The filing notes that 35,855,037 shares of the issuer’s common stock are outstanding. The 27,000 shares were acquired on 01/13/2026 through the cash exercise of an option that was granted on 04/17/2024.